Gene-editing firm CRISPR steadies after boosted $550 mln convertible debt deal

Crispr Therapeutics AG

11/03/2026 12:34

** US-listed shares of Swiss gene-editing co CRISPR Therapeutics CRSP.O up fractionally to $52.86 premarket after upsized capital raise

** Biopharma firm early Weds announces pricing private offering of $550 mln 1.125% 5-yr convertible bonds

** Initial conversion price of $76.56 represents 45% premium to stock's last close of $52.80

** CRSP shares fell 10% on Tues after co unveiled $350 mln offering for general corp purposes

** Co has $5 bln market cap

** Through Tues, US-listed shares up 0.7% YTD and 22% over the past year

** Avg rating of 29 analysts is "buy"; median PT $78, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))